Category: Pharma, Life Sciences & Med Tech Players
-
FTC urges Fourth Circuit to reverse summary judgment for Johnson & Johnson in Stelara antitrust suit: ‘specific intent not required to prove monopolization’
The U.S. Federal Trade Commission has told the Fourth Circuit that a Virginia court wrongly required proof of specific intent before CareFirst’s Stelara biosimilar-patent monopoly claims against Johnson & Johnson could proceed.
-
Federal Circuit affirms invalidation of Enanta’s Paxlovid-related patent: finds “typo” defense insufficient to fix written description gap in provisional filing
The United States Court of Appeals for the Federal Circuit has affirmed the invalidation of Enanta’s Paxlovid-related patent, rejecting its bid to blame a one-carbon typo in its provisional filing, and leaving Pfizer’s earlier disclosure now free to anticipate the claims.
-
Amgen must pay $20.2 million in damages over antibody patent infringement: District of Delaware jury
Following a trial in the United States District Court for the District of Delaware last week, a jury has found that Amgen’s subsidiary Teneobio has infringed one of competitor Harbour Antibodies’s antibody-related patents and owes over $20 million in damages.
-
Boston Scientific raises University of Texas’s alleged inflammatory comments, A-Rod comparisons in appeal of $42M District of Delaware jury verdict
Counsel compared an expert witness to the disgraced baseball player, while also suggesting that the standard for finding invalidity should be similar to deciding whether to commit someone to a psychiatric institution.
-
Incyte acquires bleeding-disorder biotech Vega Therapeutics as Jakafi patent cliff looms
Incyte will pay $1.25 billion upfront for Vega Therapeutics, with up to $750 million more in sales milestones. The $2.4 billion-a-year drug loses U.S. exclusivity in December 2028 after a pediatric extension.
-
Podcast: marking UPC’s three-year anniversary with UPC litigator Dr. Wim Maas (Winston Taylor)
In our latest podcast episode, ip fray interviewed Wim Maas, partner and trial attorney at Winston Taylor, who is a very frequent user of the Unified Patent Court.
-
Moderna appeals to save $1.3 billion patent dispute payout, asserts U.S. government-contractor immunity
Moderna has alleged that a district court’s conclusions in a case against Arbutus are “deeply flawed” and that the U.S. Congress created Section 1498 specifically to shield government contractors from liability for government-authorized patent use in fulfilling a government procurement contract.
-
Jury accepts “reverse doctrine of equivalents” defense in blood pump patent case involving Johnson & Johnson unit
Abiomed and Maquet have been engaged in a long-running battle over blood pump technology.
-
Global pharma company Adalvo eying U.S. expansion, says Chief IP Officer
While the B2B pharma company has expanded its European business significantly in the last decade, it is now turning to the U.S. to bring its licensing business, Adalvo’s Toni Santamaria told ip fray at IP Dealmakers earlier this month.
-
China Implements Pharmaceutical Test Data Protection Rules: A New Era for Drug Data Protection
China has promulgated the Measures for the Implementation of Pharmaceutical Test Data Protection and the Work Scheme for Pharmaceutical Test Data Protection, which together operationalize for the first time a formal PTDP system in China, granting up to six years of data exclusivity to qualifying chemical and biological drug applicants.